Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
431 stopped studies mapped to Urinary System Carcinoma and descendants · 87% state a reason
Over the 431 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00040989 | BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic Kidney Cancer | Phase 2 | withdrawn | Jan 27, 2003 | Jonsson Comprehensive Cancer Center | not stated | Not stated |
| NCT01073644 | Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent)… | — | terminated | Feb 23, 2010 | Pfizer | The study was prematurely discontinued due to poor recruitment on 18th April 2013. There were no… | Safety / toxicity |
| NCT00098618 | Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic… | Phase 2 | terminated | Dec 8, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01834183 | Tivozanib + Gemcitabine in Metastatic RCC | Phase 2 | withdrawn | Apr 17, 2013 | Dana-Farber Cancer Institute | Sponsor Aveo has withdrawn support for this trial. | Other (stated, no rule matched) |
| NCT00004856 | Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic… | Phase 2 | terminated | Sep 30, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01781442 | A Post Marketing Surveillance As Required By Philippine Food And Drug Administration | — | withdrawn | Feb 1, 2013 | Pfizer | not stated | Not stated |
| NCT00491075 | Pemetrexed Plus Gemcitabine in Renal Cell Cancer | Phase 2 | terminated | Jun 25, 2007 | M.D. Anderson Cancer Center | Closed early for poor accrual. | Enrollment / accrual |
| NCT01466504 | Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in… | — | terminated | Nov 8, 2011 | Dartmouth-Hitchcock Medical Center | Accrual did not meet expectations. Over nearly 2 years just 4 subjects were treated on study. The… | Enrollment / accrual |
| NCT01616186 | Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC) | Phase 2 | withdrawn | Jun 11, 2012 | Andrea Harzstark | not stated | Not stated |
| NCT00937482 | Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases… | Phase 1 | terminated | Jul 13, 2009 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00429026 | Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell… | Phase 2 | terminated | Jan 31, 2007 | M.D. Anderson Cancer Center | Slow accrual, study terminated. | Enrollment / accrual |
| NCT00601120 | RF Ablation of Treatment of Metastatic Lesions in Patients Undergoing Antiangiogenic… | N/A | withdrawn | Jan 25, 2008 | Beth Israel Deaconess Medical Center | This protocol was never officially opened and no patients were recruited. | Enrollment / accrual |
| NCT00816686 | A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced… | Phase 1 | terminated | Jan 5, 2009 | Astellas Pharma Inc | Trial was terminated due to the need to re-formulate the study drug. | Other (stated, no rule matched) |
| NCT00009919 | SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to… | Phase 2 | terminated | Jan 1, 2004 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT01245660 | A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy(LAPAINBLAD) | Early Phase 1 | terminated | Nov 22, 2010 | University Hospital, Bordeaux | The rythm of enrollment was not compatible with the objective of recruitement in the research. | Enrollment / accrual |
| NCT00082459 | Trial to Compare the Routes of Administration of an Investigational, Personalized,… | Phase 2 | terminated | May 12, 2004 | Agenus Inc. | Lack of enrollment | Enrollment / accrual |
| NCT00126178 | Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic… | Phase 3 | terminated | Aug 3, 2005 | Agenus Inc. | not stated | Not stated |
| NCT01070186 | Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma | Phase 2 | withdrawn | Feb 17, 2010 | Jonsson Comprehensive Cancer Center | No participants were enrolled. | Enrollment / accrual |
| NCT01197820 | Hepatic and Renal Thermography Using Magnetic Resonance Imaging(THeR-IRM) | N/A | terminated | Sep 9, 2010 | University Hospital, Bordeaux | not stated | Not stated |
| NCT00311467 | Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in… | Phase 3 | terminated | Apr 6, 2006 | Central European Cooperative Oncology Group | no patient recruitment | Enrollment / accrual |
| NCT00100685 | Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC) | Phase 2 | terminated | Jan 5, 2005 | Abbott | not stated | Not stated |
| NCT01033981 | Cost Effectiveness Of Sunitinib In Central America And Caribbean | — | terminated | Dec 17, 2009 | Pfizer | See termination reason in detailed description. | Other (stated, no rule matched) |
| NCT00485563 | A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive… | Phase 2 | terminated | Jun 13, 2007 | Endocyte | Changes in treatment paradigm resulted in a lower than expected rate of accrual. | Enrollment / accrual |
| NCT00561912 | Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma | Phase 2 | terminated | Nov 21, 2007 | M.D. Anderson Cancer Center | Low accrual. | Enrollment / accrual |
| NCT01441388 | A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid… | Phase 1 | withdrawn | Sep 27, 2011 | Pfizer | Business/Operational issues | Sponsor / business decision |
| NCT00065572 | Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly… | Phase 2 | suspended | Jul 31, 2003 | AstraZeneca | not stated | Not stated |
| NCT00277316 | Study of XL999 in Patients With Metastatic Renal Cell Carcinoma | Phase 2 | terminated | Jan 16, 2006 | Symphony Evolution, Inc. | Development of XL999 was stopped due to cardiac toxicities in the subjects | Safety / toxicity |
| NCT00491738 | A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in… | Phase 2 | terminated | Jun 26, 2007 | Genentech, Inc. | Based on the data collected, the combination of bevacizumab and sunitinib appeared to be poorly… | Other (stated, no rule matched) |
| NCT00417677 | A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced… | Phase 1 / Phase 2 | terminated | Jan 4, 2007 | Wyeth is now a wholly owned subsidiary of Pfizer | Decision was made not to attempt a lower dose | Other (stated, no rule matched) |
| NCT00131651 | ATN-161 in Advanced Renal Cell Cancer | Phase 2 | terminated | Aug 19, 2005 | Attenuon | not stated | Not stated |
| NCT00151645 | Efficacy of Activated Lymphocytes in Renal Cell Carcinoma. | Phase 2 | terminated | Sep 9, 2005 | Rennes University Hospital | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jul 10, 2013source: clinicaltrials